Market Place
Sourcing Support
Oncolytics Biotech® CEO Dr. Matt Coffey Takes Medical Leave Of Absence
24 Jun 2024 //
PR NEWSWIRE
ASCO Meeting Reveals Groundbreaking Oncology Data
19 Jun 2024 //
PR NEWSWIRE
Oncolytics Pelareorep Asco Abstracts: Pancreatic Moa Immunotherapy Potential
24 May 2024 //
PR NEWSWIRE
Oncolytics Biotech Announces AGM Voting Results
16 May 2024 //
PR NEWSWIRE
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
14 Feb 2024 //
PR NEWSWIRE
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
09 Jan 2024 //
PR NEWSWIRE
Oncolytics Announces Phase 1/2 Study of Pelareorep Has Met Criteria for Efficacy
09 Nov 2023 //
PR NEWSWIRE
Oncolytics and SOLTI Present Further Positive Pelareorep Translational Data
03 Nov 2023 //
PR NEWSWIRE
Oncolytics Achieves Success Criteria for Efficacy in Colorectal Cancer
23 Oct 2023 //
PR NEWSWIRE
Oncolytics Presents Positive Pancreatic Cancer Data from GOBLET Phase 1/2 Study
23 Oct 2023 //
PR NEWSWIRE
Oncolytics to Host Conference Call to Discuss Third Quarter Financial Results
20 Oct 2023 //
PR NEWSWIRE
Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units
31 Jul 2023 //
PR NEWSWIRE
Oncolytics Announces Updated Randomized Phase 2 Data from BRACELET-1 Trial
05 Jun 2023 //
PR NEWSWIRE
Oncolytics Biotech to Host Conference to Discuss First Quarter Financial Results
12 Apr 2023 //
PR NEWSWIRE
Oncolytics to Participate in Panel Presentation at Canaccord Genuity`s Horizons
12 Apr 2023 //
PR NEWSWIRE
Oncolytic virus startup TILT raises €22M to advance cancer therapies
07 Feb 2023 //
ENDPTS
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector
01 Dec 2022 //
BIONJ
Oncolytics Biotech Announces Presentations at Breast Cancer Symposium
21 Nov 2022 //
PRNEWSWIRE
Oncolytics Biotech Appoints Jonathan Rigby to its Board of Directors
07 Sep 2022 //
PRNEWSWIRE
Oncolytics Biotech to Host Conference Call to Discuss Q2 Financial Results
27 Jul 2022 //
PRNEWSWIRE
Oncolytics Biotech to Participate in a Fireside Chat at the 2022 RBC
10 May 2022 //
PRNEWSWIRE
Oncolytics Biotech Reports First Quarter 2022 Financial Results
05 May 2022 //
PRNEWSWIRE
Oncolytics Biotech, SOLTI Present New Biomarker Data of Pelareorep`s Potential
04 May 2022 //
PRNEWSWIRE
Adlai Nortye Advances Trial of Pelareorep-Paclitaxel Combo
24 Mar 2022 //
PRNEWSWIRE
Oncolytics Biotech says Publication of PC and Patient Data of Pelareorep
16 Mar 2022 //
PRNEWSWIRE
Oncolytics Bio shows phase 1b data for pelareorep-proteasome inhibitor combo
10 Mar 2022 //
PHARMABIZ
Oncolytics Biotech: Safety Update on Pancreatic Cancer Cohort of Phase 1/2 Trial
02 Feb 2022 //
PRNEWSWIRE
Oncolytics Biotech Provides Enrollment Update on Phase 1/2 GI Cancer Trial
20 Jan 2022 //
PRNEWSWIRE
Oncolytics Biotech Provides Enrollment Update on Phase 1/2 GI Cancer Trial
20 Jan 2022 //
BIOSPACE
Oncolytics Biotech Announces Positive data of Pelareorep & Radiotherapy
20 Sep 2021 //
PRNEWSWIRE
Oncolytics Biotech Reports 2021 Second Quarter Development Highlights
06 Aug 2021 //
PRESS RELEASE
Oncolytics Host Conference Call to Discuss Second Quarter Results Operational
22 Jul 2021 //
PRNEWSWIRE
Oncolytics Host Conference Call to Discuss Second Quarter Results Operational
22 Jul 2021 //
PRNEWSWIRE
Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference
30 Jun 2021 //
PR NEWSWIRE
Oncolytics Biotech, SOLTI’s AWARE-1 breast cancer study of pelareorep plus
14 Apr 2021 //
PHARMBIZ
Oncolytics Biotech, SOLTI’s AWARE-1 breast cancer study of pelareorep plus
13 Apr 2021 //
PHARMBIZ
Oncolytics Bio`s cancer-killing virus arms CAR-T cells to attack solid tumors
26 Feb 2021 //
FIERCEBIOTECH
Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic
23 Feb 2021 //
PRNEWSWIRE
Oncolytic immunotherapy biotech CG Oncology nabs $47M round
11 Dec 2020 //
FIERCEBIOTECH
Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint
09 Dec 2020 //
PRNEWSWIRE
Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint
08 Dec 2020 //
PRNEWSWIRE
Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates Ph 2 BRACELET-1
17 Nov 2020 //
ONCOLYTICSBIOTECH
Arming the rabbit pox virus to fight cancer
12 Nov 2020 //
FIERCE BIOTECH
Oncolytics Biotech® Abstract Publication and Upcoming Oral Presentation
09 Nov 2020 //
ONCOLYTICSBIOTECH
Oncolytics Biotech® Announces Abstract Publication Upcoming Oral Presentation
09 Nov 2020 //
PRNEWSWIRE
Oncolytics Biotech collaborates with Roche & AIO to begin ph 1/2 GI cancer study
28 Oct 2020 //
PHARMABIZ
Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2
26 Oct 2020 //
PRNEWSWIRE
Oncolytics Biotech® Doses First Patient in Ph2 IRENE Study Pelareorep-anti-PD-1
26 Aug 2020 //
ONCOLYTICSBIOTECH
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial
24 Jun 2020 //
PRNEWSWIRE
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study
23 Jun 2020 //
PRNEWSWIRE
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data ASCO
29 May 2020 //
ONCOLYTICSBIOTECH
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker
26 May 2020 //
PR NEWSWIRE
Oncolytics Biotech® to Clinical Findings of Pelareorep-Induced Immune Response
04 May 2020 //
PRNEWSWIRE
Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1
05 Apr 2020 //
PRNEWSWIRE
Momenta Provides Corporate Update Amid COVID-19 Pandemic
02 Apr 2020 //
BUSINESSINSIDER
Oncolytics Biotech® Announces Pub of Pelareorep`s Clinical Benefit Against KRAS
02 Apr 2020 //
PRNEWSWIRE
